Rohto Pharmaceutical Co.,Ltd.
4527.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | ¥509,483,646 | ¥685,326,552 | ¥631,945,030 | ¥421,488,650 |
| - Cash | ¥77,161,000 | ¥89,210,000 | ¥79,951,000 | ¥72,791,000 |
| + Debt | ¥50,223,000 | ¥10,494,000 | ¥11,693,000 | ¥21,383,000 |
| Enterprise Value | ¥482,545,646 | ¥606,610,552 | ¥563,687,030 | ¥370,080,650 |
| Revenue | ¥308,625,000 | ¥270,840,000 | ¥238,664,000 | ¥199,646,000 |
| % Growth | 14% | 13.5% | 19.5% | – |
| Gross Profit | ¥169,381,000 | ¥157,286,000 | ¥137,421,000 | ¥116,489,000 |
| % Margin | 54.9% | 58.1% | 57.6% | 58.3% |
| EBITDA | ¥56,424,000 | ¥50,403,000 | ¥42,338,000 | ¥35,810,000 |
| % Margin | 18.3% | 18.6% | 17.7% | 17.9% |
| Net Income | ¥31,005,000 | ¥30,936,000 | ¥26,377,000 | ¥21,127,000 |
| % Margin | 10% | 11.4% | 11.1% | 10.6% |
| EPS Diluted | 135.46 | 135.21 | 115.29 | 92.34 |
| % Growth | 0.2% | 17.3% | 24.9% | – |
| Operating Cash Flow | ¥36,917,000 | ¥34,245,000 | ¥30,924,000 | ¥27,250,000 |
| Capital Expenditures | -¥9,080,000 | -¥8,912,000 | -¥9,908,000 | -¥11,328,000 |
| Free Cash Flow | ¥27,837,000 | ¥25,333,000 | ¥21,016,000 | ¥15,922,000 |